Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples